Genetic testing may help reduce PPI-linked infections in children
Dose could be adjusted according to liver enzyme activity, expert suggests
13th November 2019
Children with a poor or normal functioning liver enzyme are at increased risk of infection when on proton pump inhibitor (PPI) therapy, compared with those with more rapid enzyme metabolism, a study shows.
US researchers carried out a retrospective analysis of 670 children aged up to three years (median age seven months, 44% girls) who were prescribed PPIs.
Children were genotyped and classified according to the rate of metabolism by their cytochrome P450 2C19 enzyme (known as CYP2C19).
